UY28081A1 - Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular - Google Patents
Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celularInfo
- Publication number
- UY28081A1 UY28081A1 UY28081A UY28081A UY28081A1 UY 28081 A1 UY28081 A1 UY 28081A1 UY 28081 A UY28081 A UY 28081A UY 28081 A UY28081 A UY 28081A UY 28081 A1 UY28081 A1 UY 28081A1
- Authority
- UY
- Uruguay
- Prior art keywords
- indolinone
- proliferacinn
- chemotherapcutic
- administracinn
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Abstract
La invención se refiere a un método de tratamiento del cáncer mediante la administración de una combinación de un compuesto de indolinona con otro agente a quimioterapéutico. La combinación de un compuesto de indolinona de Fórmula I: con otro agente quimioterapéutico provee un efecto potenciado en tratamiento del pacientes con cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42638602P | 2002-11-15 | 2002-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY28081A1 true UY28081A1 (es) | 2004-06-30 |
Family
ID=32326343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY28081A UY28081A1 (es) | 2002-11-15 | 2003-11-14 | Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular |
Country Status (22)
Country | Link |
---|---|
US (1) | US20040152759A1 (es) |
EP (1) | EP1562600A4 (es) |
JP (1) | JP2006508981A (es) |
KR (1) | KR20050086594A (es) |
CN (2) | CN101259131A (es) |
AR (1) | AR042042A1 (es) |
AU (1) | AU2003290943A1 (es) |
BR (1) | BR0315630A (es) |
CA (1) | CA2506308A1 (es) |
CO (1) | CO5700778A2 (es) |
GT (1) | GT200300245A (es) |
MX (1) | MXPA05005150A (es) |
NL (1) | NL1024779C2 (es) |
NO (1) | NO20052578L (es) |
PA (1) | PA8588601A1 (es) |
PE (1) | PE20040835A1 (es) |
PL (1) | PL376954A1 (es) |
RU (1) | RU2342140C2 (es) |
TW (1) | TW200418837A (es) |
UY (1) | UY28081A1 (es) |
WO (1) | WO2004045523A2 (es) |
ZA (1) | ZA200503841B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2318649T3 (es) | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento de preparacion de derivados de 4-fenoxi quinolinas. |
US7994159B2 (en) * | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
JP5371426B2 (ja) * | 2004-07-09 | 2013-12-18 | プロルックス ファーマシューティカルズ コープ. | ワートマニン類似体及び化学療法薬と組み合わせた同一物を使用する方法 |
US8969379B2 (en) * | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
US20090117197A1 (en) * | 2005-03-21 | 2009-05-07 | Vicus Therapeutics Llc | Compositions and methods for ameliorating cachexia |
BRPI0607579A2 (pt) * | 2005-03-23 | 2009-09-15 | Pfizer Prod Inc | uso de anticorpo anti-ctla4 e indolinona para a preparação de medicamentos para o tratamento de cáncer |
WO2006120557A1 (en) * | 2005-05-12 | 2006-11-16 | Pfizer Inc. | Anticancer combination therapy using sunitinib malate |
US20100105031A1 (en) * | 2005-08-01 | 2010-04-29 | Esai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
EP1938842A4 (en) * | 2005-09-01 | 2013-01-09 | Eisai R&D Man Co Ltd | METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS |
WO2007031833A2 (en) * | 2005-09-15 | 2007-03-22 | Council Of Scientific And Industrial Research | Novel series of imidazolyl substituted steroidal and indan-1-one derivatives |
US20090012085A1 (en) * | 2005-09-20 | 2009-01-08 | Charles Michael Baum | Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
WO2007052849A1 (ja) * | 2005-11-07 | 2007-05-10 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質とc-kitキナーゼ阻害物質との併用 |
US20090247576A1 (en) * | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
DE102006024834B4 (de) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | Neue Indol-Pyrrol-Derivate und deren Verwendungen |
JPWO2008001956A1 (ja) * | 2006-06-29 | 2009-12-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝線維症治療剤 |
CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c-Abl特异性抑制剂的新用途 |
KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
CA2676796C (en) | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
WO2009060945A1 (ja) | 2007-11-09 | 2009-05-14 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
EP2242493B1 (en) * | 2008-01-22 | 2013-06-05 | Concert Pharmaceuticals Inc. | Derivatives of gefitinib |
AU2009210098B2 (en) * | 2008-01-29 | 2013-06-13 | Eisai R & D Management Co., Ltd. | Combined use of angiogenesis inhibitor and taxane |
JP2011526615A (ja) * | 2008-07-02 | 2011-10-13 | ジェネリクス・(ユーケー)・リミテッド | 3−ピロール置換2−インドリノン誘導体の調製 |
US20100143295A1 (en) * | 2008-12-05 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | Quinazoline inhibitors of egfr tyrosine kinase |
EP2586443B1 (en) | 2010-06-25 | 2016-03-16 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
CA2828946C (en) | 2011-04-18 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
ES2705950T3 (es) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
CN103127096B (zh) * | 2011-12-02 | 2015-11-25 | 杨子娇 | 吡咯基取代的吲哚类化合物在治疗青光眼病的应用 |
US9931313B2 (en) * | 2012-04-04 | 2018-04-03 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating proliferative disorders with malate or derivatives thereof |
CN104755463A (zh) | 2012-12-21 | 2015-07-01 | 卫材R&D管理有限公司 | 非晶态形式的喹啉衍生物及其生产方法 |
MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
JO3783B1 (ar) | 2014-08-28 | 2021-01-31 | Eisai R&D Man Co Ltd | مشتق كوينولين عالي النقاء وطريقة لإنتاجه |
DK3263106T3 (da) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat |
CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
CN107801379B (zh) | 2015-06-16 | 2021-05-25 | 卫材R&D管理有限公司 | 抗癌剂 |
WO2017213245A1 (ja) * | 2016-06-09 | 2017-12-14 | 有機合成薬品工業株式会社 | 4-(ピペリジン-4-イル)モルホリンの製造方法 |
WO2021056077A1 (en) * | 2019-09-26 | 2021-04-01 | Starpharma Pty Ltd | Therapeutic dendrimer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0103617A2 (hu) * | 1998-05-29 | 2002-02-28 | Sugen, Inc. | Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása |
WO2001037820A2 (en) * | 1999-11-24 | 2001-05-31 | Sugen, Inc. | Ionizable indolinone derivatives and their use as ptk ligands |
CA2395461C (en) * | 1999-12-22 | 2010-05-25 | Sugen, Inc. | Methods of modulating c-kit tyrosine kinase function with indolinone compounds |
CA2399358C (en) * | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
MY128450A (en) * | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
WO2002081466A1 (en) * | 2001-04-09 | 2002-10-17 | Sugen, Inc. | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
-
2003
- 2003-11-13 AR ARP030104194A patent/AR042042A1/es unknown
- 2003-11-14 TW TW092132030A patent/TW200418837A/zh unknown
- 2003-11-14 PL PL376954A patent/PL376954A1/pl not_active Application Discontinuation
- 2003-11-14 PA PA20038588601A patent/PA8588601A1/es unknown
- 2003-11-14 CA CA002506308A patent/CA2506308A1/en not_active Abandoned
- 2003-11-14 BR BR0315630-3A patent/BR0315630A/pt not_active IP Right Cessation
- 2003-11-14 UY UY28081A patent/UY28081A1/es not_active Application Discontinuation
- 2003-11-14 RU RU2005118417/14A patent/RU2342140C2/ru not_active IP Right Cessation
- 2003-11-14 CN CNA2008100814220A patent/CN101259131A/zh active Pending
- 2003-11-14 EP EP03783527A patent/EP1562600A4/en not_active Withdrawn
- 2003-11-14 PE PE2003001154A patent/PE20040835A1/es not_active Application Discontinuation
- 2003-11-14 WO PCT/US2003/036526 patent/WO2004045523A2/en active Application Filing
- 2003-11-14 GT GT200300245A patent/GT200300245A/es unknown
- 2003-11-14 CN CNB200380103225XA patent/CN100430060C/zh not_active Expired - Fee Related
- 2003-11-14 JP JP2004553729A patent/JP2006508981A/ja not_active Withdrawn
- 2003-11-14 KR KR1020057008541A patent/KR20050086594A/ko not_active Application Discontinuation
- 2003-11-14 MX MXPA05005150A patent/MXPA05005150A/es unknown
- 2003-11-14 AU AU2003290943A patent/AU2003290943A1/en not_active Abandoned
- 2003-11-14 US US10/712,296 patent/US20040152759A1/en not_active Abandoned
- 2003-11-14 NL NL1024779A patent/NL1024779C2/nl not_active IP Right Cessation
-
2005
- 2005-05-11 CO CO05045078A patent/CO5700778A2/es not_active Application Discontinuation
- 2005-05-12 ZA ZA200503841A patent/ZA200503841B/en unknown
- 2005-05-27 NO NO20052578A patent/NO20052578L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CO5700778A2 (es) | 2006-11-30 |
US20040152759A1 (en) | 2004-08-05 |
NO20052578L (no) | 2005-05-27 |
CN1711089A (zh) | 2005-12-21 |
RU2342140C2 (ru) | 2008-12-27 |
WO2004045523A2 (en) | 2004-06-03 |
PE20040835A1 (es) | 2004-11-18 |
WO2004045523A3 (en) | 2004-09-30 |
AR042042A1 (es) | 2005-06-08 |
BR0315630A (pt) | 2005-08-23 |
KR20050086594A (ko) | 2005-08-30 |
NL1024779C2 (nl) | 2004-11-09 |
TW200418837A (en) | 2004-10-01 |
RU2005118417A (ru) | 2006-01-20 |
ZA200503841B (en) | 2006-09-27 |
MXPA05005150A (es) | 2005-07-22 |
AU2003290943A1 (en) | 2004-06-15 |
PA8588601A1 (es) | 2004-05-21 |
EP1562600A2 (en) | 2005-08-17 |
GT200300245A (es) | 2004-06-23 |
EP1562600A4 (en) | 2008-06-25 |
CA2506308A1 (en) | 2004-06-03 |
CN100430060C (zh) | 2008-11-05 |
NL1024779A1 (nl) | 2004-05-18 |
PL376954A1 (pl) | 2006-01-09 |
CN101259131A (zh) | 2008-09-10 |
JP2006508981A (ja) | 2006-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY28081A1 (es) | Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular | |
MX2019011530A (es) | Saxitoxinas 11,13-modificadas para el tratamiento del dolor. | |
EA200500859A1 (ru) | Хинолинилпирролопиразолы | |
EA201791669A3 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
IS2696B (is) | Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð | |
LU92338I2 (fr) | Enzalutamide et ses sels pharmaceutiquement acceptables (XTANDI) | |
AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
MX344587B (es) | Metodo para incrementar la estabilidad in vitro e in vivo de enzimas asociadas al transtorno lisosomal. | |
MX2007004955A (es) | Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente. | |
UY28255A1 (es) | Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger | |
DE60125417D1 (de) | Verminderung der nebenwirkungen der chemotherapie in krebspatienten | |
CY1111353T1 (el) | Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης | |
NO20056170L (no) | Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839 | |
TR200002203T2 (tr) | Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi. | |
NO20064754L (no) | Kombinasjonsterapi | |
MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. | |
DOP2003000756A (es) | Administracion de una combinacion de una indolinona con un agente quimioterapeutico para los trastornos de la proliferacion celular | |
TW200509922A (en) | Methods of therapeutic treatment using amounts of retinoid components | |
AR043241A1 (es) | Terapia combinada que comprende un derivado de indolpirrol-carbazol y otro agente antitumoral | |
NO20051601L (no) | Kombinasjonsterapi med gemcitabin og zd6126 | |
EA200600987A1 (ru) | Применение сирамезина в лечении злокачественных опухолей | |
SG124310A1 (en) | Treatment of skin diseases | |
UA3370U (uk) | Спосіб лікування центральної хоріоретинальної дистрофії |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20160120 |